In a therapeutic tumor vaccine study, vaccination against an antigen expressed in both tumors and normal tissues was able to induce low-avidity antigen-specific CD8+ T cells to reject tumor cells with high levels of target antigen expression, while remaining tolerant of antigen-expressing pancreatic beta cells [176]. This evidence concerns the gene CD8A and neoplasm.